Valuation Shifts Across Key North American Stocks

Recent analysis across multiple North American-listed companies highlights a wide dispersion between market prices and intrinsic value estimates. Healthcare, financial data, consumer staples, industrial technology and auto components names are all being reassessed after sharp multi-period share moves, with discounted cash flow (DCF) models, price-to-earnings (P/E) ratios and narrative-based fair values offering differing signals.

UnitedHealth Group Incorporated (UNH) has introduced Avery, an AI companion designed to help members navigate benefits and administrative tasks such as appointment scheduling, cost estimates, claim status checks and provider searches. Launched on March 26, 2026, Avery initially serves about 6.5 million employer-sponsored and 160,000 Medicare Advantage members, with management targeting 20.5 million commercial, Medicare and Medicaid members by year-end 2026.

Avery uses generative AI, and the company reports that roughly 90% of interactions do not require human assistance, which could improve operating efficiency. The AI tool integrates benefits, claims and provider data on a single platform and is supported by Optum’s software and analytics capabilities.

UnitedHealth (UNH) shares recently fell 3.3% to around $259, below 50-day and 200-day moving averages of approximately $291.83 and $323.04. Over one month the stock is down 6.49%, broadly in line with sector declines of 7.36%. The company trades on a trailing P/E of 19.65 and a PEG ratio of 1.24, with a market capitalization of about $235.23 billion and beta of 0.41.

Analyst consensus rates the stock Moderate Buy, with an average price target of $372.13 and a forward P/E of 15.15. Q1 2026 earnings on April 21 are a key near-term focus, with consensus EPS of $6.62 on revenue of $110.08 billion, compared with prior-quarter revenue of $113.73 billion and EPS of $2.11.

FactSet Research Systems has experienced prolonged share price pressure, with a 90-day decline of 32.11% and a one-year total shareholder return loss of 55.16%. The shares recently rose 1.05% in a day to $198.33, despite the company generating US$2,360.7 million in revenue and US$599.6 million in net income across its global footprint.

A popular narrative-based valuation pegs FactSet’s fair value at $313.99 per share, implying material upside from the last close. The narrative emphasizes recurring infrastructure revenues built around four strategic platforms: Cobalt in private markets, CUSIP in global standards, Vermilion in reporting and Portware in execution.

A separate fundamental review describes FactSet as a financial data and analytics provider with subscription-based, recurring revenues and a long-standing dividend profile. Institutional investors have adjusted positions amid market volatility, and some independent assessments characterize the shares as undervalued given the firm’s competitive moat in financial data services.

STERIS plc, a leader in sterilization and infection prevention products for hospitals, pharmaceutical manufacturers and medical device companies, continues to attract institutional demand. Wealth Enhancement Advisory Services LLC increased its STERIS holdings by 23.5% in Q4 to 26,763 shares worth $6.97 million. Vanguard, State Street, Orbis Allan Gray, Mitsubishi UFJ Asset Management and Invesco are among large holders, contributing to institutional ownership of 94.69%.

The stock opened at $219.90, with a 50-day moving average of $242.75 and a 200-day moving average of $248.76. STERIS reported quarterly EPS of $2.53, matching consensus, up from $2.32 a year earlier, on revenue that grew 9.2% year over year. Net margin was 12.15% and return on equity 14.34%. The company pays a quarterly dividend of $0.63 per share, or $2.52 annually, for a yield of about 1.1% and a payout ratio of 35.15%.

Analysts tracked by MarketBeat assign STERIS an average rating of Moderate Buy, with six Buy and two Hold ratings and a consensus price target of $275.20. The company has issued FY 2026 EPS guidance of 10.15 to 10.30, while analysts expect current-year EPS of 9.08.

In consumer staples, Simply Wall St’s DCF model values J. M. Smucker at about $299.32 per share versus a recent price of $95.24, implying the stock is 68.2% undervalued on that metric. The company’s P/S ratio of 1.14x sits above the food industry average of 0.77x but below its own Fair Ratio of 1.27x, and is therefore also described as undervalued on that tailored P/S basis.

In the industrial and technology sphere, Advanced Energy Industries is highlighted for strong share price performance but stretched valuation. A DCF estimate of $140.81 per share compares with a market price of $310.76, suggesting the stock trades 120.7% above that intrinsic value estimate. The company’s P/E of 78.58x also sits well above an industry average of 28.76x and a Fair Ratio of 44.75x, leading to an overvalued assessment on both DCF and P/E checks.

Other valuation-focused updates include FirstService, where a DCF estimate of $188.14 is close to the share price of about $186.55, implying fair value overall despite a one-year share price decline of 21.1%. PHINIA’s DCF-based intrinsic value of $114.24 per share stands above its recent $67.11 price, but its current P/E of 19.57x is slightly higher than a Fair Ratio of 18.21x, resulting in mixed signals across methods.

Super Micro Computer, active in AI-related server hardware, shows a DCF-derived intrinsic value of $37.61 per share versus a recent price of $21.97, implying a 41.6% discount. The company trades on a P/E of 15.12x, below both the broader tech industry average of 22.07x and a Fair Ratio of 52.88x, and is characterized as undervalued on these models after a 35.9% one-year share price decline.

Amprius Technologies, focused on silicon anode lithium-ion batteries for aviation and unmanned systems, has rallied sharply, with 30-day and 90-day price returns of 50.23% and 103.54%, and a one-year shareholder return of 473.67%. A widely followed narrative assigns a fair value of $19.25 versus a recent price around $16.12, describing the stock as 16.3% undervalued and tying its prospects to scaling production supported by contracts such as a $10.5 million Defense Innovation Unit award.